TL;DR: Vitamin D is far more than a bone nutrient — it is a neurosteroid with receptors distributed across critical brain regions including the hippocampus, prefrontal cortex, and substantia nigra. Over one billion people worldwide have insufficient levels, and observational research consistently associates low vitamin D status with faster cognitive decline and higher dementia risk. However, large randomized controlled trials such as VITAL-Cog have not shown clear cognitive benefits from supplementing people who are already vitamin D-sufficient. The practical conclusion: testing your levels is important, correcting deficiency is a priority, and mega-dosing beyond sufficiency is unlikely to help. Fatty fish, fortified foods, sensible sun exposure, and D3 supplementation (typically 1000-2000 IU/day) are the most effective strategies.

Introduction

Vitamin D occupies a peculiar position in the landscape of brain health nutrients. On one hand, the biological case for its importance in the central nervous system is compelling — vitamin D receptors and the enzymes needed to activate the hormone are expressed throughout the brain, and laboratory research has identified clear neuroprotective mechanisms. On the other hand, the clinical trial evidence for cognitive benefits from supplementation has been frustratingly inconsistent, creating a gap between what the biology predicts and what the randomized trials have demonstrated so far.

This tension is worth understanding rather than glossing over. Vitamin D is not a simple story, and overselling it as a cognitive wonder-supplement would be as misleading as dismissing its relevance to the brain entirely. The truth, as is often the case in nutritional neuroscience, lies in the details — who is deficient, how severe the deficiency is, when in life it occurs, and what outcomes we are measuring.

What is not in dispute is this: vitamin D deficiency is extraordinarily common worldwide, and the brain is one of many organs that depends on adequate levels to function properly. Understanding the mechanisms, the epidemiological evidence, the trial data, and the practical strategies for optimization is worth your time — especially if you are among the roughly one billion people globally who are currently running low.

Vitamin D Receptors in the Brain

The discovery that changed our understanding of vitamin D’s role beyond calcium metabolism came when researchers identified vitamin D receptors (VDR) and the enzyme 1-alpha-hydroxylase (CYP27B1) — the enzyme that converts circulating 25-hydroxyvitamin D into its active form, 1,25-dihydroxyvitamin D (calcitriol) — in human brain tissue. This was first comprehensively mapped by Eyles et al. (2005), who used immunohistochemistry to document VDR expression across multiple brain regions in the adult human brain.

The distribution is not random. Vitamin D receptors are concentrated in areas of the brain that are central to cognition, memory, and executive function:

  • Hippocampus — the primary structure for memory encoding and spatial navigation, and one of the first regions to degenerate in Alzheimer’s disease.
  • Prefrontal cortex — responsible for planning, decision-making, working memory, and impulse control.
  • Cingulate gyrus — involved in emotion regulation, attention, and error detection.
  • Substantia nigra — the dopamine-producing region whose degeneration causes Parkinson’s disease.
  • Hypothalamus — a critical regulatory hub for sleep, appetite, stress response, and circadian rhythms.

The presence of both VDR and CYP27B1 in these regions means the brain is not merely a passive recipient of circulating vitamin D — it actively converts the prohormone into its active form locally, suggesting region-specific, tightly regulated functions that go well beyond calcium homeostasis. Vitamin D, in the brain, behaves more like a neurosteroid than a simple vitamin.

Neuroprotective Mechanisms

The biological pathways through which vitamin D influences brain function have been the subject of extensive laboratory research. Several mechanisms have been identified with sufficient consistency to be considered well-established.

Neurotrophic Factor Regulation

Vitamin D upregulates the expression of nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF) — two proteins essential for the survival, growth, and maintenance of neurons. NGF is particularly important in the basal forebrain cholinergic system, the same network of neurons that degenerates early in Alzheimer’s disease. Brown et al. (2003) demonstrated that calcitriol increased NGF synthesis in hippocampal cultures, suggesting a direct mechanism by which vitamin D could support the neuronal populations most vulnerable to age-related decline.

GDNF is critical for the survival of dopaminergic neurons in the substantia nigra, linking vitamin D status to Parkinson’s disease risk — a connection that has been supported by multiple epidemiological studies.

Anti-inflammatory Action

Chronic neuroinflammation is now recognized as a central driver of neurodegeneration. Activated microglia — the brain’s resident immune cells — produce pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) that, when chronically elevated, damage neurons and synapses. Vitamin D exerts potent anti-inflammatory effects within the central nervous system by suppressing pro-inflammatory cytokine production and promoting the release of anti-inflammatory mediators such as IL-10.

Fernandes de Abreu et al. (2009) reviewed the immunomodulatory role of vitamin D in the brain and concluded that its ability to dampen chronic neuroinflammation represents one of the most plausible mechanisms linking deficiency to neurodegeneration. This is particularly relevant given that neuroinflammation tends to increase with age — precisely the period when vitamin D deficiency becomes most prevalent.

Antioxidant Defense

Vitamin D enhances the expression of gamma-glutamyl transpeptidase, an enzyme involved in glutathione synthesis. Glutathione is the brain’s primary endogenous antioxidant, and its depletion is a consistent feature of neurodegenerative disease. By supporting glutathione production, vitamin D helps protect neurons against oxidative stress — one of the core mechanisms of cellular damage in both normal aging and dementia.

Amyloid Beta Clearance

One of the more intriguing findings in recent years has been the demonstration that vitamin D enhances the clearance of amyloid beta, the protein fragment whose accumulation into plaques is the hallmark pathological feature of Alzheimer’s disease. Masoumi et al. (2009) showed that calcitriol stimulated macrophage-mediated phagocytosis of amyloid beta in brain tissue from Alzheimer’s patients. While this does not prove that vitamin D supplementation can prevent or reverse Alzheimer’s disease, it identifies a biologically plausible pathway that connects vitamin D status to the disease’s central pathology.

Neurotransmitter Synthesis

Vitamin D influences the expression of genes involved in the synthesis of several neurotransmitters, including serotonin, dopamine, and acetylcholine. Patrick and Ames (2014) proposed a detailed model in which vitamin D regulates tryptophan hydroxylase 2 (TPH2), the enzyme that produces serotonin in the brain. Low vitamin D status, by this mechanism, could contribute to reduced brain serotonin levels — with downstream implications for mood, impulse control, and executive function.

Global Prevalence of Vitamin D Deficiency

The scope of vitamin D insufficiency worldwide is staggering. A comprehensive meta-analysis by Hilger et al. (2014), published in the British Journal of Nutrition, pooled data from 195 studies across 44 countries and found that approximately 37 percent of the global population had serum 25(OH)D levels below 50 nmol/L (20 ng/mL) — the threshold most commonly used to define deficiency. When the threshold is raised to 75 nmol/L (30 ng/mL), which many researchers consider the minimum for optimal health, the prevalence of insufficiency exceeds one billion people worldwide.

Several factors drive this widespread shortfall:

Latitude and sun exposure. Vitamin D synthesis in the skin requires UVB radiation at a wavelength of 290-315 nm. At latitudes above approximately 35 degrees north or south, UVB intensity during winter months is insufficient to produce meaningful vitamin D, regardless of time spent outdoors. This creates a natural “vitamin D winter” affecting populations throughout northern Europe, Canada, the northern United States, and comparable southern latitudes.

Indoor lifestyles. Even in sunny climates, modern populations spend the vast majority of their time indoors. Office workers, students, and older adults in care facilities receive far less UVB exposure than their outdoor-working counterparts. Air pollution, window glass (which blocks UVB), and sunscreen use further reduce cutaneous synthesis.

Skin pigmentation. Melanin absorbs UVB radiation, which means that individuals with darker skin require substantially more sun exposure — in some estimates, three to five times more — to produce the same amount of vitamin D as lighter-skinned individuals. This has significant public health implications: studies consistently show that Black and South Asian populations in northern countries have markedly higher rates of vitamin D deficiency. Forrest and Stuhldreher (2011) found that 82 percent of Black Americans and 69 percent of Hispanic Americans had 25(OH)D levels below 50 nmol/L, compared to 30 percent of white Americans.

Age. The skin’s capacity to synthesize vitamin D declines with age. A 70-year-old produces approximately 25 percent of the vitamin D that a 20-year-old produces from the same UVB exposure. Coupled with reduced outdoor activity and dietary changes, this makes older adults — precisely the group most vulnerable to cognitive decline — especially susceptible to deficiency.

Obesity. Vitamin D is fat-soluble and is sequestered in adipose tissue. Individuals with obesity have consistently lower circulating 25(OH)D levels, even after controlling for sun exposure and dietary intake. Wortsman et al. (2000) demonstrated that obese individuals produce the same amount of vitamin D in their skin as lean individuals but release it into the circulation less efficiently.

Observational Evidence: Low Vitamin D and Cognitive Decline

The epidemiological literature linking vitamin D status to cognitive outcomes is extensive and, on balance, remarkably consistent. While observational studies cannot prove causation, the pattern across dozens of prospective cohorts is difficult to dismiss.

The Cardiovascular Health Study

Slinin et al. (2012) analyzed data from 6,257 community-dwelling older women in the Study of Osteoporotic Fractures and found that those with 25(OH)D levels below 50 nmol/L had significantly higher odds of cognitive impairment at baseline and a greater likelihood of cognitive decline over four years of follow-up, even after adjusting for age, education, physical activity, depression, and other confounders.

The Health ABC Study

Llewellyn et al. (2010) followed 858 adults aged 65 and older from the InCHIANTI study in Italy over six years. Participants with severely deficient 25(OH)D levels (below 25 nmol/L) experienced cognitive decline on the Mini-Mental State Examination (MMSE) at a rate 60 percent faster than those with sufficient levels. This association remained significant after extensive covariate adjustment.

The Whitehall II Study

Llewellyn et al. (2011) examined cognitive function in 3,369 men aged 40-79 in the European Male Ageing Study and found that low vitamin D was associated with slower information processing speed — a domain particularly sensitive to early neurodegeneration.

Alzheimer’s and Dementia Risk

A landmark meta-analysis by Balion et al. (2012) pooled data from 37 studies and found that participants with low 25(OH)D levels had significantly lower MMSE scores and a higher prevalence of Alzheimer’s disease compared to those with adequate levels. More recently, Littlejohns et al. (2014) followed 1,658 ambulatory adults from the Cardiovascular Health Study for a mean of 5.6 years. They found that participants who were severely deficient in vitamin D (below 25 nmol/L) had more than double the risk of developing all-cause dementia and Alzheimer’s disease compared to those with sufficient levels. This was one of the first large prospective studies to specifically examine incident dementia rather than prevalent cognitive impairment, strengthening the case for a temporal relationship.

A major 2023 study by Ghahremani et al. in Alzheimer’s & Dementia analyzed data from over 12,000 participants in the National Alzheimer’s Coordinating Center (NACC) dataset. They found that vitamin D supplementation was associated with a 40 percent lower incidence of dementia over a 10-year follow-up period, with particularly strong effects observed in women and APOE4 non-carriers. While still observational in nature, the sample size and longitudinal design added considerable weight to the existing evidence.

Limitations of Observational Data

It is important to acknowledge the key limitation of all observational evidence: confounding. People with low vitamin D status are more likely to be older, less physically active, more obese, more socially isolated, and more likely to have chronic diseases — all of which independently increase dementia risk. While statistical adjustment can account for measured confounders, unmeasured or residual confounding cannot be eliminated. Reverse causation is also a concern: people in the early, pre-clinical stages of dementia may go outdoors less and eat less well, resulting in lower vitamin D levels as a consequence of the disease rather than a cause.

This is precisely why randomized controlled trials are needed.

Randomized Controlled Trials: What the Evidence Shows

VITAL-Cog

The most important trial addressing vitamin D and cognitive function is VITAL-Cog, a cognitive sub-study of the Vitamin D and Omega-3 Trial (VITAL). VITAL was a large randomized, double-blind, placebo-controlled trial that enrolled 25,871 men aged 50 and older and women aged 55 and older across the United States. Participants were randomized to receive 2000 IU/day of vitamin D3 (cholecalciferol) or placebo, with a 2x2 factorial design that also tested omega-3 fatty acid supplementation.

VITAL-Cog, led by Manson and colleagues, assessed cognitive outcomes in a subset of over 3,400 participants using validated telephone-based cognitive assessments over a median follow-up of 5.3 years. The results, published in 2023, found no significant difference between the vitamin D and placebo groups on any measure of global cognition, executive function, or memory.

This was disappointing to many, but not entirely surprising. The trial enrolled a generally healthy, vitamin D-replete population — the mean baseline 25(OH)D level was approximately 77 nmol/L (31 ng/mL), well above the deficiency threshold. Only about 12 percent of participants were deficient at baseline. In other words, VITAL-Cog was, by design, poorly positioned to detect benefits from supplementation, because most participants did not need supplementation in the first place.

Subgroup analyses suggested a possible benefit among Black participants, who had lower baseline vitamin D levels, though these analyses were not powered for definitive conclusions.

DO-HEALTH

The DO-HEALTH trial (Bischoff-Ferrari et al., 2020) was a European multi-center trial in 2,157 adults aged 70 and older that tested 2000 IU/day of vitamin D3, omega-3 fatty acids, and a simple home exercise program, alone and in combination. After three years, no significant cognitive benefits were observed for vitamin D supplementation in the overall cohort. However, as with VITAL-Cog, the mean baseline vitamin D level was relatively high (approximately 55 nmol/L), and the population was generally healthy.

Smaller Trials and Deficient Populations

Several smaller trials have tested vitamin D supplementation in populations with lower baseline levels, with more encouraging — though far from definitive — results. Jorde et al. (2019) conducted a randomized trial in Norway and found no overall cognitive benefit from high-dose vitamin D supplementation, but did observe improvements in a subgroup with the lowest baseline levels.

Rossom et al. (2012) analyzed data from the Women’s Health Initiative (WHI) and found that combined calcium and vitamin D supplementation (at a relatively low dose of 400 IU/day) did not reduce dementia or cognitive impairment risk over 7.8 years — though the dose used is widely considered inadequate by modern standards.

The pattern across trials is consistent: supplementing people who already have adequate vitamin D levels does not measurably improve cognition. What remains inadequately tested is whether correcting genuine deficiency — particularly in high-risk populations such as older adults, individuals with dark skin living at high latitudes, or those with early cognitive impairment — can prevent or slow cognitive decline. This is the critical unanswered question.

Food Sources of Vitamin D

Unlike most nutrients, vitamin D is present in relatively few foods. The body’s primary source under natural conditions is cutaneous synthesis from UVB exposure — making dietary sources supplementary rather than primary. Nevertheless, in modern indoor-dwelling populations, food and supplements are often the main determinants of vitamin D status.

Fatty fish — the richest natural dietary source. Wild-caught salmon provides approximately 600-1000 IU per 3.5 oz (100 g) serving; farmed salmon typically provides less, in the range of 100-250 IU. Mackerel, sardines, herring, and trout are also excellent sources, providing 200-500 IU per serving. Canned tuna provides roughly 150-250 IU per serving. Consuming fatty fish two to three times per week provides a meaningful base of dietary vitamin D alongside omega-3 fatty acids.

Cod liver oil — a traditional source that delivers approximately 400-1000 IU per teaspoon, depending on the brand. It also provides vitamin A and omega-3s, but the high vitamin A content means intake should be moderated.

Egg yolks — a modest source, providing approximately 40-50 IU per large egg. Eggs from pasture-raised hens exposed to sunlight may contain substantially more — some studies have measured levels three to four times higher than conventional eggs.

Mushrooms exposed to UV light — the only meaningful plant-based source. When mushrooms (maitake, shiitake, portobello, or white button) are exposed to UVB radiation (either sunlight or commercial UV treatment), they produce vitamin D2 (ergocalciferol) in substantial amounts — up to 400-800 IU per serving. Some commercially available mushrooms are now sold with enhanced vitamin D content noted on the label. While D2 is somewhat less effective than D3 at raising serum 25(OH)D levels over time, UV-treated mushrooms are a valuable option for vegetarians and vegans.

Fortified foods — many countries fortify milk, orange juice, breakfast cereals, and plant-based milk alternatives with vitamin D, typically at 100-150 IU per serving. In Nordic countries, fortification of dairy and margarine has been implemented as public health policy. While fortified foods contribute to population-level intake, the amounts per serving are generally too small to correct deficiency on their own.

Supplementation: D3 vs D2, Dosing, and Testing

D3 vs D2

Supplemental vitamin D comes in two forms: vitamin D3 (cholecalciferol, derived from animal sources or lichen) and vitamin D2 (ergocalciferol, derived from fungi). Multiple studies, including a meta-analysis by Tripkovic et al. (2012) in the American Journal of Clinical Nutrition, have demonstrated that D3 is significantly more effective than D2 at raising and maintaining serum 25(OH)D levels. D3 has a higher affinity for vitamin D-binding protein and a longer half-life in circulation.

For these reasons, D3 is the preferred form for supplementation. Vegan-friendly D3 sourced from lichen is now widely available, eliminating the need for vegans to rely on the less effective D2 form.

Dosing

Current recommended dietary allowances (RDAs) set by the Institute of Medicine are 600 IU/day for adults aged 19-70 and 800 IU/day for adults over 70. However, many researchers and clinical organizations consider these targets too conservative, arguing that they were set primarily to prevent bone disease rather than to optimize broader health outcomes including neurological function.

The Endocrine Society’s clinical practice guidelines recommend 1500-2000 IU/day for adults to maintain 25(OH)D levels above 75 nmol/L (30 ng/mL). Many vitamin D researchers, including those who have studied its neurological effects, advocate for similar or slightly higher targets.

A reasonable evidence-based approach for most adults:

  • If deficient (below 50 nmol/L / 20 ng/mL): A loading protocol of 5000-10,000 IU/day for 8-12 weeks under medical supervision, followed by a maintenance dose.
  • For maintenance: 1000-2000 IU/day of D3. This dose is safe, well within the Tolerable Upper Intake Level of 4000 IU/day set by the IOM, and sufficient to maintain levels in the optimal range for most individuals.
  • Obese individuals: May require two to three times higher doses due to volumetric dilution and sequestration in adipose tissue.

The Tolerable Upper Intake Level is 4000 IU/day, though toxicity from supplementation is extremely rare at doses below 10,000 IU/day. True vitamin D toxicity, characterized by hypercalcemia, typically occurs only with prolonged intake above 40,000-50,000 IU/day or due to manufacturing errors.

Testing

The standard biomarker for vitamin D status is serum 25-hydroxyvitamin D [25(OH)D]. This is the circulating storage form and reflects combined input from sun exposure, diet, and supplements. Most laboratories report results in either nmol/L or ng/mL (1 ng/mL = 2.5 nmol/L).

Generally accepted ranges:

  • Deficient: Below 50 nmol/L (20 ng/mL)
  • Insufficient: 50-75 nmol/L (20-30 ng/mL)
  • Sufficient: 75-125 nmol/L (30-50 ng/mL)
  • Potentially excessive: Above 150 nmol/L (60 ng/mL)

Testing is particularly worthwhile for individuals in high-risk groups (discussed below). A single blood test, repeated once or twice per year (end of winter and end of summer), provides the information needed to calibrate supplementation accurately.

Sun Exposure Considerations

Sunlight remains the most efficient source of vitamin D for the human body. Exposing large areas of skin (arms, legs, torso) to midday UVB radiation for 10-30 minutes can produce 10,000-20,000 IU of vitamin D — far more than any dietary source. However, several practical factors complicate the recommendation to “just get more sun.”

Latitude and season. As noted, UVB intensity at latitudes above 35 degrees north is insufficient for vitamin D synthesis during winter months. In London (51 degrees N), Boston (42 degrees N), or Berlin (52 degrees N), there may be six months per year when the sun angle is too low for meaningful cutaneous production.

Skin cancer risk. Prolonged UVB exposure is a well-established risk factor for skin cancer. Dermatological organizations generally recommend sun protection to reduce cancer risk, which creates a direct tension with the vitamin D synthesis message. The resolution is not to choose one extreme — no sun or unlimited sun — but to find a practical middle ground.

A sensible approach: expose arms and legs to midday sun (between approximately 10 AM and 2 PM, when UVB intensity peaks) for 10-20 minutes, two to three times per week, during months when the sun angle permits. This brief, sub-sunburn exposure allows meaningful vitamin D production without substantially increasing skin cancer risk. Apply sunscreen after this initial exposure window for any continued time outdoors. During months when UVB is unavailable, rely on supplementation.

Skin pigmentation. Darker-skinned individuals need substantially more UVB exposure to produce equivalent vitamin D. This is a physiological adaptation to ancestral equatorial UV environments that becomes maladaptive at higher latitudes. Supplementation is especially important for this group.

Who Is Most at Risk

Several populations face elevated risk for vitamin D deficiency and its potential cognitive consequences:

Older adults. Reduced skin synthesis capacity, less time outdoors, lower dietary intake, and impaired intestinal absorption all converge to make people over 65 the single highest-risk group. This is compounded by the fact that this is also the population most vulnerable to cognitive decline.

People with dark skin at high latitudes. As detailed above, melanin reduces UVB-mediated vitamin D synthesis. Black and South Asian populations living in northern Europe, Canada, or the northern United States have deficiency rates two to three times higher than lighter-skinned populations in the same regions.

Obese individuals. The sequestration of vitamin D in adipose tissue reduces bioavailability. Obese individuals typically require higher supplemental doses to achieve the same serum levels as lean individuals.

People with limited sun exposure. This includes office workers, shift workers, institutionalized elderly, individuals who cover most of their skin for religious or cultural reasons, and people in northern climates during winter.

Individuals with malabsorption conditions. Celiac disease, inflammatory bowel disease, Crohn’s disease, and any condition affecting fat absorption can impair vitamin D uptake from food and supplements.

People taking certain medications. Anticonvulsants (phenytoin, carbamazepine), glucocorticoids, and some antiretroviral drugs can accelerate vitamin D metabolism, increasing requirements.

Practical Takeaway

  1. Get tested. A serum 25(OH)D test is the only reliable way to know your vitamin D status. Request one from your physician, particularly if you fall into any high-risk group. Target a level of 75-100 nmol/L (30-40 ng/mL).

  2. Eat fatty fish regularly. Two to three servings per week of salmon, mackerel, sardines, or trout provides a meaningful dietary base of vitamin D alongside omega-3 fatty acids — a combination with compounding brain health benefits.

  3. Supplement with D3, not D2. For most adults, 1000-2000 IU/day of vitamin D3 is a safe and effective maintenance dose. Take it with a meal containing fat to optimize absorption. Vegan D3 from lichen is widely available.

  4. Get brief, regular sun exposure when possible. Ten to twenty minutes of midday sun on exposed skin, two to three times per week during appropriate months, supports natural vitamin D production. Do not burn.

  5. Correct deficiency aggressively. If your levels are below 50 nmol/L, work with a healthcare provider to implement a loading dose protocol before transitioning to a maintenance dose.

  6. Do not mega-dose without testing. There is no evidence that pushing vitamin D levels far above the sufficient range provides additional cognitive benefits, and very high levels carry a risk of hypercalcemia. More is not always better.

  7. Pay extra attention if you are in a high-risk group. Older adults, individuals with dark skin at northern latitudes, obese individuals, and those with malabsorption conditions should treat vitamin D optimization as a priority rather than an afterthought.

Frequently Asked Questions

Can vitamin D supplements prevent dementia?

The honest answer is that we do not yet know definitively. Observational studies consistently show that people with low vitamin D have higher dementia risk, and the biological mechanisms are plausible. However, the largest randomized controlled trials (VITAL-Cog, DO-HEALTH) have not demonstrated dementia prevention from supplementation — though these trials predominantly enrolled people with adequate baseline levels. What the evidence does support is that deficiency is harmful to the brain and should be corrected. Whether supplementation beyond sufficiency provides additional protection remains an open question that future trials targeting deficient populations will need to answer.

What is the optimal vitamin D level for brain health?

While the precise optimal level for cognitive function has not been established through definitive trial evidence, most of the observational data suggest that the risk of cognitive decline begins to increase below approximately 50-75 nmol/L (20-30 ng/mL). A reasonable target based on current evidence is 75-100 nmol/L (30-40 ng/mL). There is no convincing evidence that levels above 125 nmol/L (50 ng/mL) provide additional cognitive benefit.

Is vitamin D deficiency a cause of dementia or just a marker?

This is the central unresolved question. The biology strongly supports a causal role — vitamin D receptors are present throughout the brain, and the neuroprotective mechanisms (neurotrophic factor support, anti-inflammatory action, amyloid clearance) are well-documented in laboratory studies. However, the failure of large RCTs to show cognitive benefits from supplementation (albeit in largely replete populations) leaves the door open for confounding and reverse causation in the observational data. The most balanced interpretation is that deficiency likely contributes causally to cognitive decline, but it is probably one of many factors rather than a dominant driver.

Should I take vitamin D with vitamin K2?

Vitamin K2 is often recommended alongside vitamin D to direct calcium into bones rather than soft tissues. This is based on sound physiological reasoning — vitamin D increases calcium absorption, while vitamin K2 activates proteins that guide calcium to appropriate destinations. However, the clinical evidence for cognitive benefits from adding K2 specifically is limited. If you are supplementing with vitamin D at moderate doses (1000-2000 IU/day) and eating a reasonably balanced diet, K2 co-supplementation is a reasonable but not essential addition. It becomes more relevant at higher vitamin D doses or for individuals with cardiovascular calcification concerns.

How long does it take to correct vitamin D deficiency?

With appropriate supplementation (typically 5000-10,000 IU/day under medical supervision), most people can raise their 25(OH)D levels from deficient to sufficient within 8-12 weeks. Maintenance doses of 1000-2000 IU/day can then sustain adequate levels year-round. The response depends on baseline levels, body weight, absorption capacity, and concurrent sun exposure. Retesting after 2-3 months of supplementation is recommended to confirm that the dose is appropriate.

Sources

  • Eyles, D. W., Smith, S., Kinobe, R., Hewison, M., & McGrath, J. J. (2005). Distribution of the vitamin D receptor and 1-alpha-hydroxylase in human brain. Journal of Chemical Neuroanatomy, 29(1), 21–30.

  • Brown, J., Bianco, J. I., McGrath, J. J., & Eyles, D. W. (2003). 1,25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neuroscience Letters, 343(2), 139–143.

  • Fernandes de Abreu, D. A., Tremblay, P., Bherer, L., & Bhatt, D. (2009). Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology, 34(Suppl 1), S265–S277.

  • Masoumi, A., Goldenson, B., Ghirmai, S., Avagyan, H., Zaghi, J., Abel, K., … & Bhatt, D. (2009). 1-alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer’s disease patients. Journal of Alzheimer’s Disease, 17(3), 703–717.

  • Patrick, R. P., & Ames, B. N. (2014). Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. The FASEB Journal, 28(6), 2398–2413.

  • Hilger, J., Friedel, A., Herr, R., Rausch, T., Roos, F., Wahl, D. A., … & Hoffmann, K. (2014). A systematic review of vitamin D status in populations worldwide. British Journal of Nutrition, 111(1), 23–45.

  • Forrest, K. Y., & Stuhldreher, W. L. (2011). Prevalence and correlates of vitamin D deficiency in US adults. Nutrition Research, 31(1), 48–54.

  • Littlejohns, T. J., Henley, W. E., Lang, I. A., Annweiler, C., Beauchet, O., Chaves, P. H., … & Llewellyn, D. J. (2014). Vitamin D and the risk of dementia and Alzheimer disease. Neurology, 83(10), 920–928.

  • Llewellyn, D. J., Lang, I. A., Langa, K. M., Muniz-Terrera, G., Phillips, C. L., Cherubini, A., … & Melzer, D. (2010). Vitamin D and risk of cognitive decline in elderly persons. Archives of Internal Medicine, 170(13), 1135–1141.

  • Balion, C., Griffith, L. E., Strifler, L., Henderson, M., Patterson, C., Heckman, G., … & Raina, P. (2012). Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology, 79(13), 1397–1405.

  • Slinin, Y., Paudel, M., Taylor, B. C., Ishani, A., Rossom, R., Yaffe, K., … & Ensrud, K. E. (2012). Association between serum 25(OH) vitamin D and the risk of cognitive decline in older women. The Journals of Gerontology Series A, 67(10), 1092–1098.

  • Ghahremani, M., Smith, E. E., Chen, H. Y., Creese, B., Goodarzi, Z., & Bhatt, D. (2023). Vitamin D supplementation and incident dementia: effects of sex, APOE, and baseline cognitive status. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 15(1), e12404.

  • Manson, J. E., Cook, N. R., Lee, I. M., Christen, W., Bassuk, S. S., Mora, S., … & Buring, J. E. (2019). Vitamin D supplements and prevention of cancer and cardiovascular disease. The New England Journal of Medicine, 380(1), 33–44.

  • Bischoff-Ferrari, H. A., Vellas, B., Rizzoli, R., Theiler, R., Dawson-Hughes, B., Egli, A., … & Orav, E. J. (2020). Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA Internal Medicine, 180(10), 1345–1355.

  • Tripkovic, L., Lambert, H., Hart, K., Smith, C. P., Bucca, G., Penson, S., … & Lanham-New, S. (2012). Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. The American Journal of Clinical Nutrition, 95(6), 1357–1364.

  • Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000). Decreased bioavailability of vitamin D in obesity. The American Journal of Clinical Nutrition, 72(3), 690–693.

  • Rossom, R. C., Espeland, M. A., Manson, J. E., Dysken, M. W., Johnson, K. C., Lane, D. S., … & Wallace, R. B. (2012). Calcium and vitamin D supplementation and cognitive impairment in the Women’s Health Initiative. Journal of the American Geriatrics Society, 60(12), 2197–2205.